Does Lamivudine And Tenofovir Disoproxil Fumarate Interact with Sofosbuvir?
Lamivudine And Tenofovir Disoproxil Fumarate and Sofosbuvir have a moderate drug interaction according to U.S. FDA drug labeling data. 7.3 Hepatitis C Antiviral Agents Coadministration of TDF, a component of CIMDUO, and EPCLUSA ® (sofosbuvir/velpatasvir) or HARVONI ® (ledipasvir/sofosbuvir) has been shown to increase tenofovir exposure [see Clinical Pharmacology (12.3) ] . In patients receiving TDF concomitantly with sofosbuvir/velpatasvir, monitor for adverse reactions associated with TDF. In patients receiving CIMDUO concomitantly with ledipasvir/sofosbuvir without an HIV-1 protease inhibitor/ritonavir or an HIV-1 protease inhibitor/cobicistat combination, monitor for adverse reactions associated with tenofovir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Lamivudine And Tenofovir Disoproxil Fumarate Class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Sofosbuvir Class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Lamivudine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Sofosbuvir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider